Lymphoma CancerPhase 1NCT07838649
Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity
A Phase 1 study testing 68Ga-Galmydar, PET/MRI and 18F-FDG in people with Lymphoma Cancer and Breast Cancer, run by Washington University School of Medicine at 1 site in United States.
Trial summary
This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or lymphoma undergoing treatment with anthracycline for cancer therapy. Read more about this study
- Who is it for?
- Ages 21 to 99 years
- Conditions the study is for
- Lymphoma Cancer, Breast Cancer, Cancer of the Breast
- What is being tested?
- 68Ga-Galmydar, PET/MRI and 18F-FDG
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Nov 2026to 12 Dec 2029
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men and women, 21-99 years of age and any race
- Normal left ventricular function (left ventricular ejection fraction (LVEF) >50%) as determined by echocardiography
- HER2 positive or negative breast cancer patients or lymphoma patients
- Designated to receive standard of care (SOC) treatment with an anthracycline-containing regimen including combination therapy
- Patients willing to adhere to fasting for 15 hours before 18F-FDG PET imaging studies (if applicable)
Who cannot join
- Inability to receive and sign informed consent
- Prior exposure to anthracyclines or other cardiotoxic drug
- Contraindications to anthracycline chemotherapy
- Patients with history of myocardial infarction
- Patients with fasting blood sugar >200 mg/dL or <70 mg/dL and symptomatic
- Contraindications to MR imaging (ferromagnetic implants, pacemaker, brain aneurysm clips, shrapnel, claustrophobia, etc.)
Show all 9Show fewer
- Pregnant or lactating. All female subjects of childbearing potential must have a documented negative pregnancy test (serum or urine hCG) performed within 24 hours immediately prior to the administration of 68Ga-Galmydar or documented post-menopausal defined as the cessation of menses for ≥ 12 months or documentation of having a bilateral oophorectomy and/or hysterectomy.
- Any condition that in the opinion of the Principal Investigator or designee could increase risk to the participant, limit the participant's ability to tolerate the research procedures or interfere with collection of the data such as:
- Inability to lie still or unable to tolerate a supine position with arms up over the head or down at sides for up to a 60-minute PET scan due to chronic back/shoulder pain or arthritis as assessed by physical examination and/or medical history
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Washington University School of Medicine
St Louis, Missouri, 63110
Molly Mohrman, 314-747-4633, mohrmanm@wustl.edu
Pamela Woodard, MD, 314-362-7100, woodardp@wustl.edu
About this study
Official title: PET Imaging of Chemotherapy-Induced Cardiotoxicity
This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or lymphoma undergoing treatment with anthracycline for cancer therapy.
- Conditions
- Lymphoma Cancer, Breast Cancer, Cancer of the Breast, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- Being tested
- 68Ga-Galmydar, PET/MRI, 18F-FDG
- Keywords
- Positron Emission Tomography (PET), Cardiotoxicity, Cardiovascular disease, Chemotherapy-induced cardiac dysfunction, Chemotherapy-induced heart failure, Anthracycline, Doxorubicin, Adriamycin
- Medical subject headings
- Breast Neoplasms, Lymphoma, Non-Hodgkin, Hodgkin Disease, Cardiotoxicity, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
68Ga-GalmydarDrug
Also called Ga-Galmydar
68Ga-Galmydar is a positron-emitting radioisotope used prior to PET/MRI imaging. Prior to imaging, patients will receive one single intravenous administration of 2.5 mCi ± 20% (2.0-3.0 mCi) of 68Ga-Galmydar followed by a 10 mL normal saline flush on Imaging Day -1.
PET/MRIDevice
Also called Positron Emission Tomography/Magnetic Resonance Imaging, PET/MR, PET-MRI
Patients will undergo PET/MRI according to standard of care imaging.
18F-FDGDrug
Also called F-FDG, FDG
18F-FDG is administered by an intravenous injection of 10 mCi ± 20% (8-12 mCi) followed by a 10 mL normal saline flush.
| Study group | Role | What they receive |
|---|---|---|
| 68Ga-Galmydar + PET Imaging | Experimental | Lymphoma patients: baseline prior to the start of chemotherapy treatment, after the patient has had at least 250 mg/m^2 of anthracycline (after the 5th cycle \& before the 6th cycle of anthracycline in Non-Hodgkin lymphoma or after the 5th cycle (10 treatments) in Hodgkin lymphoma, 1-3 weeks after the 5th cycle of anthracycline), and 12-months (+/- 1 month) post-treatment
Breast patients: baseline prior to the start of all chemotherapy treatments, baseline after Paclitaxel and prior to the start of AC (Adriamycin \& Cyclophosphamide) for patients treated with the Keynote-522 regimen, 1-2 weeks after the last dose (4 cycles) of AC, and 12-months (+/- 1 month) post-treatment
Echocardiography will be performed at all PET imaging sessions \& at 6- and 9-months post-chemotherapy
A subset of 3 breast \& 3 lymphoma patients will undergo 18F-FDG PET/MRI. Patients undergoing 18F-FDG PET/MRI will stay overnight \& will be imaged with 18F-FDG in the morning on day 2 under fasting conditions Receives: Drug: 68Ga-Galmydar; Device: PET/MRI; Drug: 18F-FDG |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in 68Ga-Galmydar Standardized Uptake Value (SUV) in patients with and without cardiotoxicity
The ability of 68Ga-Galmydar PET/MRI to detect chemotherapy-induced cardiotoxicity will be determined by measuring changes in PET signal (SUV) over time in patients with and without cardiotoxicity. Classification of whether or not a patient develops cardiotoxicity will be determined by evaluation of the left ventricular ejection fraction (LVEF) on echocardiography. Cardiac SUVmean values between pre- and post-chemotherapy will be obtained from PET scans. SUV quantifies the percent of radiotracer that accumulates in a region compared with if the tracer was distributed throughout the body.
Mixed effects regression (MER) will be used to examine decreased uptake in those with cardiotoxicity compared to those without toxicity. The regression coefficient for time-by-group interaction will describe the different time trend of SUV uptake over time between two groups.
Measured: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Correlation between 68Ga-Galmydar PET signal and the 18F-FDG PET signal
The relationship between 68Ga-Galmydar PET signal to 18F-FDG PET signal will be indicated using a Pearson or Spearman coefficient, whichever is appropriate.
Spearman's correlation coefficient evaluates the association and the association's direction between two ranked continuous variables. Spearman's correlation coefficient ranges from -1 to 1, with a negative number indicating a negative relationship between variables and a positive number indicating a positive relationship between variables. Values closer to zero indicate a weak relationship.
Pearson's correlation coefficient is a measure that evaluates the association between two continuous variables with the assumption that the variables have a linear relationship. Pearson's correlation coefficient ranges from -1 to 1, with a negative number indicating a negative relationship between variables and a positive number indicating a positive relationship between variables. Values closer to zero indicate a weak relationship.
Measured: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Correlation of PET signal and Left Ventricular Ejection Fraction (LVEF) from echocardiography
Echocardiography will be conducted prior to starting chemotherapy, at each of the PET/MR visits, and at 6 and 9-months post-chemotherapy for left ventricular function assessment. LVEF is the percentage of blood in the heart's left ventricle that ejects with each contraction. LVEF is calculated by the following equation: LVEF = (End Diastolic Volume (EDV) - End Systolic Volume (ESV)) / EDV × 100 The relationship between LVEF changes and LV-SUV will be assessed similarly with a Pearson correlation.
Measured: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Correlation of PET signal and Left Ventricular Ejection Fraction (LVEF) from MR
MR will be performed with each PET imaging scan. LVEF is the percentage of blood in the heart's left ventricle that ejects with each contraction. LVEF is calculated by the following equation: LVEF = (End Diastolic Volume (EDV) - End Systolic Volume (ESV)) / EDV × 100 The relationship between LVEF changes and LV-SUV will be assessed similarly with a Pearson correlation.
Measured: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Secondary outcomes (8)
Sensitivity of 68Ga-Galmydar
Sensitivity is calculated as the proportion of true positives divided by the sum of true positives and false negatives. Rate of sensitivity and corresponding 95% confidence interval will be reported.
Measured: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Specificity of 68Ga-Galmydar
Specificity is calculated as the proportion of true negatives divided by the sum of true negatives and false positives. Rate of specificity and corresponding 95% confidence interval will be reported.
Measured: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Comparison of segmental 68Ga-Galmydar PET SUV to native T1 values from MR
The myocardial wall segment analysis will be performed using the American Heart Association (AHA) model.
Measured: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Comparison of global 68Ga-Galmydar PET SUV to native T1 values from MR
Measured: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Comparison of segmental 68Ga-Galmydar PET SUV to native T2 values from MR
The myocardial wall segment analysis will be performed using the American Heart Association (AHA) model.
Measured: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Comparison of global 68Ga-Galmydar PET SUV to native T2 values from MR
Measured: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Comparison of global 68Ga-Galmydar PET SUV to global longitudinal strain from MR
Measured: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Comparison of global 68Ga-Galmydar PET SUV to global circumferential strain from MR
Measured: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2026
- Study start1 Nov 2026 (estimated)
- Primary completion12 Dec 2029 (estimated)
- Study completion12 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lymphoma CancerStudies of the same condition, open and under way.
- More trials run by Washington University School of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Washington University School of Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Sponsor
- Investigators
- Pamela K Woodard, MD, Principal investigator, Washington University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07838649
- Sponsor's protocol ID
- 202608159
- Other IDs
- 1R01HL180913-01
- Status last verified
- Sep 2026
- First submitted
- 17 Sep 2026
- Last updated
- 24 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: The raw data from the project (MRI, PET, CMP, CBC, Lipid panel, demographic, clinical data, including demographic, along with details on the dose administered) will be preserved and shared. All data will be de-identified prior to receipt by the repository. PET imaging and clinical data will be deposited into Open-Access Series of Imaging Studies (OASIS). Metadata and data dictionary will be shared and made accessible.
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PET Imaging of Chemotherapy-Induced Cardiotoxicity
- ClinicalTrials.gov ID
- NCT07838649
- Acronym / sponsor ID
- 202608159
- Conditions
- Lymphoma Cancer, Breast Cancer, Cancer of the Breast, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- Keywords
- Positron Emission Tomography (PET), Cardiotoxicity, Cardiovascular disease, Chemotherapy-induced cardiac dysfunction, Chemotherapy-induced heart failure, Anthracycline, Doxorubicin, Adriamycin
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- Washington University School of MedicineUniversity, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 12 Dec 2029 (estimated)
- Study completion
- 12 Dec 2029 (estimated)
- First posted
- 24 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or lymphoma undergoing treatment with anthracycline for cancer therapy.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 68Ga-Galmydar + PET Imaging | Experimental | Drug: 68Ga-Galmydar, Device: PET/MRI, Drug: 18F-FDGLymphoma patients: baseline prior to the start of chemotherapy treatment, after the patient has had at least 250 mg/m^2 of anthracycline (after the 5th cycle \& before the 6th cycle of anthracycline in Non-Hodgkin lymphoma or after the 5th cycle (10 treatments) in Hodgkin lymphoma, 1-3 weeks after the 5th cycle of anthracycline), and 12-months (+/- 1 month) post-treatment Breast patients: baseline prior to the start of all chemotherapy treatments, baseline after Paclitaxel and prior to the start of AC (Adriamycin \& Cyclophosphamide) for patients treated with the Keynote-522 regimen, 1-2 weeks after the last dose (4 cycles) of AC, and 12-months (+/- 1 month) post-treatment Echocardiography will be performed at all PET imaging sessions \& at 6- and 9-months post-chemotherapy A subset of 3 breast \& 3 lymphoma patients will undergo 18F-FDG PET/MRI. Patients undergoing 18F-FDG PET/MRI will stay overnight \& will be imaged with 18F-FDG in the morning on day 2 under fasting conditions |
Who may qualify
- Ages
- 21 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Men and women, 21-99 years of age and any race
- Normal left ventricular function (left ventricular ejection fraction (LVEF) >50%) as determined by echocardiography
- HER2 positive or negative breast cancer patients or lymphoma patients
- Designated to receive standard of care (SOC) treatment with an anthracycline-containing regimen including combination therapy
- Patients willing to adhere to fasting for 15 hours before 18F-FDG PET imaging studies (if applicable)
Key exclusion criteria (9 listed)
- Inability to receive and sign informed consent
- Prior exposure to anthracyclines or other cardiotoxic drug
- Contraindications to anthracycline chemotherapy
- Patients with history of myocardial infarction
- Patients with fasting blood sugar >200 mg/dL or <70 mg/dL and symptomatic
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 68Ga-GalmydarAlso: Ga-Galmydar68Ga-Galmydar is a positron-emitting radioisotope used prior to PET/MRI imaging. Prior to imaging, patients will receive one single intravenous administration of 2.5 mCi ± 20% (2.0-3.0 mCi) of 68Ga-Galmydar followed by a 10 mL normal saline flush on Imaging Day -1. | Drug | 68Ga-Galmydar + PET Imaging |
| PET/MRIAlso: Positron Emission Tomography/Magnetic Resonance Imaging, PET/MR, PET-MRIPatients will undergo PET/MRI according to standard of care imaging. | Device | 68Ga-Galmydar + PET Imaging |
| 18F-FDGAlso: F-FDG, FDG18F-FDG is administered by an intravenous injection of 10 mCi ± 20% (8-12 mCi) followed by a 10 mL normal saline flush. | Drug | 68Ga-Galmydar + PET Imaging |
Primary outcome
Changes in 68Ga-Galmydar Standardized Uptake Value (SUV) in patients with and without cardiotoxicity
Time frame: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
The ability of 68Ga-Galmydar PET/MRI to detect chemotherapy-induced cardiotoxicity will be determined by measuring changes in PET signal (SUV) over time in patients with and without cardiotoxicity. Classification of whether or not a patient develops cardiotoxicity will be determined by evaluation of the left ventricular ejection fraction (LVEF) on echocardiography. Cardiac SUVmean values between pre- and post-chemotherapy will be obtained from PET scans. SUV quantifies the percent of radiotracer that accumulates in a region compared with if the tracer was distributed throughout the body. Mixed effects regression (MER) will be used to examine decreased uptake in those with cardiotoxicity compared to those without toxicity. The regression coefficient for time-by-group interaction will describe the different time trend of SUV uptake over time between two groups.
Correlation between 68Ga-Galmydar PET signal and the 18F-FDG PET signal
Time frame: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
The relationship between 68Ga-Galmydar PET signal to 18F-FDG PET signal will be indicated using a Pearson or Spearman coefficient, whichever is appropriate. Spearman's correlation coefficient evaluates the association and the association's direction between two ranked continuous variables. Spearman's correlation coefficient ranges from -1 to 1, with a negative number indicating a negative relationship between variables and a positive number indicating a positive relationship between variables. Values closer to zero indicate a weak relationship. Pearson's correlation coefficient is a measure that evaluates the association between two continuous variables with the assumption that the variables have a linear relationship. Pearson's correlation coefficient ranges from -1 to 1, with a negative number indicating a negative relationship between variables and a positive number indicating a positive relationship between variables. Values closer to zero indicate a weak relationship.
Correlation of PET signal and Left Ventricular Ejection Fraction (LVEF) from echocardiography
Time frame: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Echocardiography will be conducted prior to starting chemotherapy, at each of the PET/MR visits, and at 6 and 9-months post-chemotherapy for left ventricular function assessment. LVEF is the percentage of blood in the heart's left ventricle that ejects with each contraction. LVEF is calculated by the following equation: LVEF = (End Diastolic Volume (EDV) - End Systolic Volume (ESV)) / EDV × 100 The relationship between LVEF changes and LV-SUV will be assessed similarly with a Pearson correlation.
Correlation of PET signal and Left Ventricular Ejection Fraction (LVEF) from MR
Time frame: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
MR will be performed with each PET imaging scan. LVEF is the percentage of blood in the heart's left ventricle that ejects with each contraction. LVEF is calculated by the following equation: LVEF = (End Diastolic Volume (EDV) - End Systolic Volume (ESV)) / EDV × 100 The relationship between LVEF changes and LV-SUV will be assessed similarly with a Pearson correlation.
8 secondary outcomes
Sensitivity of 68Ga-Galmydar
Time frame: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Specificity of 68Ga-Galmydar
Time frame: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Comparison of segmental 68Ga-Galmydar PET SUV to native T1 values from MR
Time frame: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Comparison of global 68Ga-Galmydar PET SUV to native T1 values from MR
Time frame: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Comparison of segmental 68Ga-Galmydar PET SUV to native T2 values from MR
Time frame: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Comparison of global 68Ga-Galmydar PET SUV to native T2 values from MR
Time frame: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Comparison of global 68Ga-Galmydar PET SUV to global longitudinal strain from MR
Time frame: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Comparison of global 68Ga-Galmydar PET SUV to global circumferential strain from MR
Time frame: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2026.
- Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of MedicineLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. The raw data from the project (MRI, PET, CMP, CBC, Lipid panel, demographic, clinical data, including demographic, along with details on the dose administered) will be preserved and shared. All data will be de-identified prior to receipt by the repository. PET imaging and clinical data will be deposited into Open-Access Series of Imaging Studies (OASIS). Metadata and data dictionary will be shared and made accessible.
Related trials for Lymphoma Cancer
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RecruitingPhase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-hodgkin Lymphoma
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
Not yet recruitingPhase 1
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma
Active, not recruitingPhase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Pamela K Woodard, MD principal investigator
Washington University School of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing 68Ga-Galmydar, PET/MRI and 18F-FDG in people with Lymphoma Cancer and Breast Cancer, run by Washington University School of Medicine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 24 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Molly Mohrman (314-747-4633, mohrmanm@wustl.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in 68Ga-Galmydar Standardized Uptake Value (SUV) in patients with and without cardiotoxicity (time frame: From baseline imaging through 12 months post treatment imaging (total estimated time 57-58 weeks)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2026.